To reinforce the concept that the Crizotinib—ALK binding pattern revealed by CETSA is useful in predicting Crizotinib sensitivity, we established two Crizotinib-resistant ALK+ALCL cell clones derived from Karpas 299 and SupM2. Here, ALK is linked to anaplastic large cell lymphoma.